Anne Marie Robertson
Executive Vice President, EVERSANA ONCOLOGY Commercialization™
Expertise:
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional teams. Specifically, Anne Marie has a record of successfully launching oncology therapies, such as Erbitux, Inlyta and Akynzeo, as well as developing new indications for in-market therapies. Her ability to set launch strategy and create science-based differentiation allows Anne Marie to leverage marketing strategies for clients globally while establishing and meeting launch metrics and driving overall brand value.
Anne Marie has an MBA from Baruch College of the City University of New York and a Bachelor of Science in biology from Rensselaer Polytechnic Institute. Early in her career Anne Marie was a U.S. Peace Corps Volunteer in Central Africa.
Articles by Anne Marie Robertson
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent engaging and informative webinar hosted by EVERSANA, EVERSANA experts Maneesh Gupta, Jennifer Meeuwsen and Anne Marie Robertson, Executive Vice President, EVERSANA ONCOLOGY Commercialization were joined by Corey Fishman, Chief Executive Officer, Iterum Therapeutics plc. They explored the critical challenges faced by new biopharma entrants and examined effective strategies to ensure successful product launches. The session focused on four major obstacles commonly encountered by first-time launchers: Ineffectiveness: First-time launchers typically generate three times less net revenue than experienced launchers. Capital Intensity: Average in-house drug launch costs reach approximately $247 million from three years pre-launch through the launch year. Time Intensity: Launch preparation often spans 24 months. High Risk: […]
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy cancer cells. Historically limited to later lines of treatment due to potential side effects and the need for individualized manufacturing, recent data support its use in earlier lines of therapy. Discover the importance of bridging education gaps among community healthcare providers, building outpatient infrastructure with manufacturer collaboration and facilitating referral shifts from specialized centers to community practices. Understand the challenges faced by community cancer centers in providing CAR-T therapies and the need […]
Behind the Breakthroughs and Practice-Changing Advances: Insights from ESMO 2024
Every year, the European Society for Medical Oncology (ESMO) brings together experts from pharma, research and advocacy organizations, and healthcare providers (HCPs) to hear about the year’s biggest oncology breakthroughs. With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. EVERSANA was there with teams from across the U.S. and EU. Here are a few of the things we learned and some associated implications heading into 2025. Artificial intelligence in oncology: AI was finally featured at a major oncology conference, with presentations including presidential symposia and conference booths establishing its place in the […]
FDA Guidance and Considerations for Scientific Exchange Communication Strategies
In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk and opportunity for more informative conversations between pharmaceutical manufacturer representatives and healthcare providers (HCPs) regarding the care of individual patients. In this new article by Anne Marie Robertson and Tim Lewis, discover top-level considerations for SIUU guidance across various channels and how it may impact manufacturers and their field force strategies. Some topics discussed throughout the article include: Context of the FDA guidance Field usage Guidance history Considerations for SIUU communications across media, website […]
Evolving Dynamics in Oncology: Considerations for Overcoming Commercialization Challenges and Driving Greater Impact
The oncology market is experiencing rapid growth, driven by innovations in therapies like biomarker-directed and cell-and-gene therapies. These advancements contribute to improved overall and progression-free survival in various cancer types. However, challenges arise from accelerated approvals and meeting confirmatory trials, leading to withdrawals of oncology drugs. With the increasing complexity of data, navigating regulatory intricacies, and launching products at record speeds, manufacturers face hurdles in infrastructure development, risk spending, and effectively communicating the value of therapies. In this latest article authored by Anne Marie Robertson, Suzanne Greenwood and Sneha Varma to view key considerations to bolster your oncology and hematology drug commercial strategy. Download the full POV now.
Transforming Pharmaceutical Commercialization: Eight Key Insights for Success
Unlock the keys to successful pharmaceutical commercialization with our latest article: “Transforming Pharmaceutical Commercialization: Eight Key Insights for Success.” This insightful piece explores crucial, actionable strategies to transform your approach to drug launch. Here’s a glimpse of what you’ll discover: Eight Key Insights for Success 1. Tailor Your Team: Learn why scaling your team to fit the asset regulatory timeline is crucial for success. 2. Empower Your Teams: Establish a governance structure that empowers your teams and fits your organization’s culture. 3. Integrate Clinical and Commercial: Drive better outcomes by integrating clinical and commercial teams from the start. 4. Engage Stakeholders: Understand the importance of stakeholder engagement in shaping […]
Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies
Personalized cancer immunotherapies are emerging as a revolutionary approach to cancer treatment, aiming to provide individualized therapies based on a patient’s specific genetic makeup. The FDA has not yet approved any personalized cancer immunotherapies, creating an intense race within pharma to be the first mover. These therapies have the potential to overcome the limitations of conventional treatments and show efficacy across different patient populations. However, commercializing these therapies poses challenges related to pricing, turnaround times, manufacturability, scalability, and patient access. Despite the enormous opportunities personalized cancer immunotherapies present, there are several challenges to overcome: Manufacturing and administration processes differ from traditional therapies, requiring improvements in production efficiency and ease of […]
Accelerated Approval Pathways: Manufacturers Left to Grapple With Risk Versus Reward
Oncology and hematology are extremely complex, crowded and chaotic therapeutic areas. With 30% of drug approvals by the FDA occurring in the oncology and hematology space, manufacturers of these high-science brands are often faced with unprecedented pressure to accelerate their oncology product launch timeline. To add an additional layer of complexity, manufacturers may opt to enter their product into a confirmatory trial, which allows the FDA to fast-track drug approvals in disease states where patients have little to no quality treatment options. Accelerated pathways pose two key challenges: The FDA is becoming more stringent, leading to an increased likelihood of product withdrawals due to negative data. Manufacturers do not have […]
Pivot Pros: How EVERSANA Course Corrected When the Market Changed
Traditional commercialization models lack the insights, flexibility and agility to synthesize and react to real-time data. If you needed to quickly pivot your strategy to ensure the success of your therapy in market, would your commercialization partner be prepared to act in your best interest? In this case study, EVERSANA’s oncology experts respond to a change in the marketplace to increase patient onboarding. The Situation: New data post-launch changed the treatment landscape. Other therapies revealed strong survival in earlier lines of therapy, causing a change in the treatment sequence and shifting other products into later lines of therapy. The Response: With the built-in flexibility of our COMPLETE Commercialization model, EVERSANA […]
Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem
As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500 active cell and gene therapy agents in clinical development, with a great momentum building for immuno-oncology treatments. The Oncology Ecosystem Is Changing, and the Cost for Commercialization Is Steep. There is no question about the incredible clinical impact these long-awaited therapies can have on patients and the industry, but launching in the oncology space is not the same as it was 20 years ago for two reasons: Commercialization stakes are high. The average cost […]
PharmaVOICE Webinar: Next Gen Commercialization Model for Oncology
In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a need for next gen commercial models.